Successful use of trametinib and dasatinib combined with chemotherapy in the treatment of Ph-positive B-cell acute lymphoblastic leukemia A case report

被引:1
作者
Wang, Jing [1 ]
Shen, Shu-Hong [2 ]
Hu, Bin-Fei [1 ]
Wang, Guan-Ling [1 ]
机构
[1] Ningbo Women & Childrens Hosp, 339 Liuting St, Ningbo 315000, Zhejiang, Peoples R China
[2] Shanghai Jiao Tong Univ, Shanghai Childrens Med Ctr, Shanghai, Peoples R China
关键词
acute lymphoblastic leukemia; case report; chemotherapy; targeted drug; trametinib; ASPARAGINASE-ASSOCIATED PANCREATITIS;
D O I
10.1097/MD.0000000000026440
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rationale: Relapsed or refractory acute lymphoblastic leukemia poses a significant clinical challenge due to its poor prognosis, showing survival rates of less than a year even with the use of novel therapies. In this report, we describe the safe and effective use of trametinib combined with dasatinib in a patient with acute lymphoblastic leukemia (ALL). To the best of our knowledge, this is the first report on the successful use of 2 targeted drugs such as trametinib and dasatinib in a pediatric patient with Ph+ ALL and recurrent pancreatitis. Patient concerns: A 6-year-old boy with ALL and Philadelphia chromosome (Ph+) who had recurrent asparaginase-associated pancreatitis. Diagnosis: The patient was diagnosed with ALL, based on clinical features, laboratory analyses, bone marrow aspiration evaluation in morphology, immunology, cytogenetics, and molecular. Interventions: The patient was treated with dasatinib combined with an intermediate risk-oriented chemotherapy. However, owing to recurrent asparaginase-associated pancreatitis, the patient has to abandon asparaginase in consolidation. Considering the high risk of relapse, we used trametinib and dasatinib combined with chemotherapy as maintenance chemotherapy. Outcomes: After 6 months, there were no obvious side effects or residual disease. Lessons: We suggest that the combination of trametinib and dasatinib may represent a viable option to treat patients with potential relapsed/refractory Ph+ ALL.
引用
收藏
页数:5
相关论文
共 18 条
[1]   Identification of a Triple Drug Combination That Is Synergistically Cytotoxic for Triple-Negative Breast Cancer Cells Using a Novel Combination Discovery Approach [J].
Ahmad, Syed ;
He, Qingping ;
Williams, Kevin P. ;
Scott, John E. .
SLAS DISCOVERY, 2020, 25 (08) :923-938
[2]  
Aldoss I, 2013, BLOOD, V122, P3915
[3]   Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase-Driven Leukemias and Other Malignancies [J].
Bruner, J. Kyle ;
Ma, Hayley S. ;
Li, Li ;
Qin, Alice Can Ran ;
Rudek, Michelle A. ;
Jones, Richard J. ;
Levis, Mark J. ;
Pratz, Keith W. ;
Pratilas, Christine A. ;
Small, Donald .
CANCER RESEARCH, 2017, 77 (20) :5554-5563
[4]   Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia [J].
Dördelmann, M ;
Reiter, A ;
Borkhardt, A ;
Ludwig, WD ;
Götz, N ;
Viehmann, S ;
Gadner, H ;
Riehm, H ;
Schrappe, M .
BLOOD, 1999, 94 (04) :1209-1217
[5]   MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia [J].
Jones, Courtney L. ;
Gearheart, Christy M. ;
Fosmire, Susan ;
Delgado-Martin, Cristina ;
Evensen, Nikki A. ;
Bride, Karen ;
Waanders, Angela J. ;
Pais, Faye ;
Wang, Jinhua ;
Bhatla, Teena ;
Bitterman, Danielle S. ;
de Rijk, Simone R. ;
Bourgeois, Wallace ;
Dandekar, Smita ;
Park, Eugene ;
Burleson, Tamara M. ;
Madhusoodhan, Pillai Pallavi ;
Teachey, David T. ;
Raetz, Elizabeth A. ;
Hermiston, Michelle L. ;
Mueschen, Markus ;
Loh, Mignon L. ;
Hunger, Stephen P. ;
Zhang, Jinghui ;
Garabedian, Michael J. ;
Porter, Christopher C. ;
Carroll, William L. .
BLOOD, 2015, 126 (19) :2202-2212
[6]   Clinical Course and Outcome in Children With Acute Lymphoblastic Leukemia and Asparaginase-Associated Pancreatitis [J].
Kearney, Susan L. ;
Dahlberg, Suzanne E. ;
Levy, Donna E. ;
Voss, Stephan D. ;
Sallan, Stephen E. ;
Silverman, Lewis B. .
PEDIATRIC BLOOD & CANCER, 2009, 53 (02) :162-167
[7]   Trametinib inhibits RAS-mutant MLL-rearranged acute lymphoblastic leukemia at specific niche sites and reduces ERK phosphorylation in vivo [J].
Kerstjens, Mark ;
Pinhancos, Sandra S. ;
Castro, Patricia Garrido ;
Schneider, Pauline ;
Wander, Priscilla ;
Pieters, Rob ;
Stam, Ronald W. .
HAEMATOLOGICA, 2018, 103 (04) :E147-E150
[8]   Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia [J].
Liu, Chengcheng ;
Yang, Wenjian ;
Devidas, Meenakshi ;
Cheng, Cheng ;
Pei, Deqing ;
Smith, Colton ;
Carroll, William L. ;
Raetz, Elizabeth A. ;
Bowman, W. Paul ;
Larsen, Eric C. ;
Maloney, Kelly W. ;
Martin, Paul L. ;
Mattano, Leonard A., Jr. ;
Winick, Naomi J. ;
Mardis, Elaine R. ;
Fulton, Robert S. ;
Bhojwani, Deepa ;
Howard, Scott C. ;
Jeha, Sima ;
Pui, Ching-Hon ;
Hunger, Stephen P. ;
Evans, William E. ;
Loh, Mignon L. ;
Relling, Mary V. .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (18) :2133-+
[9]   Blockade of MEK/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene [J].
Nishioka, Chie ;
Ikezoe, Takayuki ;
Yang, Jing ;
Takeshita, Ayako ;
Taniguchi, Ayuko ;
Komatsu, Naoki ;
Togitani, Kazuto ;
Koeffler, H. Phillip ;
Yokoyama, Akihito .
LEUKEMIA RESEARCH, 2008, 32 (06) :865-872
[10]   Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia [J].
Packer, Leisl M. ;
Rana, Sareena ;
Hayward, Robert ;
O'Hare, Thomas ;
Eide, Christopher A. ;
Rebocho, Ana ;
Heidorn, Sonja ;
Zabriskie, Matthew S. ;
Niculescu-Duvaz, Ion ;
Druker, Brian J. ;
Springer, Caroline ;
Marais, Richard .
CANCER CELL, 2011, 20 (06) :715-727